Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Recruiting

Phase 2

Phase 3

VericiguatEfficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT05714085

Conditions

Heart Failure

Left Ventricular Systolic Dysfunction

Eligibility Criteria

Sex: All

Age: 29 - 17

Healthy Volunteers: Not accepted

Interventions

Vericiguat tablet

Vericiguat suspension

Placebo tablet

Placebo suspension

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-14. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-09-10.